Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Siriraj Hospital
• Treatments: Mitomycin; Ranibizumab

Criteria

Inclusion Criteria:

• Consecutive patients with neovascular glaucoma

• Age more than 80 year old

• Provide written informed consent

Exclusion Criteria:

• Un-cooperated patients